<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00591409</url>
  </required_header>
  <id_info>
    <org_study_id>P05956</org_study_id>
    <secondary_id>19.4.208A</secondary_id>
    <nct_id>NCT00591409</nct_id>
  </id_info>
  <brief_title>A Bridging Trial Comparing Org 25969 at Reappearance of T2 in Japanese and Caucasian Subjects. Part A: Japanese Subjects (19.4.208A)(P05956)</brief_title>
  <official_title>A Multi-Center, Randomized, Open-Label, Prospective Bridging, Parallel Dose-Finding Trial Comparing Efficacy, Safety and Pharmacokinetics of 4 Doses of Org 25969 and Placebo Administered at Reappearance of T2 After Rocuronium or Vecuronium in Japanese and Caucasian Subjects. Part A: Japanese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the trial was to establish the dose-response of T2 in Japanese and Caucasian
      Subjects. Part A: Japanese Subjects
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For most surgical procedures a depth of neuromuscular block of 1-2 twitches after
      TOF-stimulation is sufficient to avoid unwanted muscular activity. At reappearance of T2, the
      anesthesiologist might decide to either give (another) maintenance dose of rocuronium or
      vecuronium when surgery continues, to await spontaneous recovery of neuromuscular block or to
      reverse the neuromuscular block. Org 25969 has been shown in previous trials to greatly
      reduce the time to full recovery when administered at reappearance of T2, both after
      rocuronium- and vecuronium-induced neuromuscular blockade. The current trial 19.4.208A was
      conducted in Japan and set up to establish the dose-response relationship of Org 25969 given
      during sevoflurane anesthesia at reappearance of T2 after rocuronium or vecuronium in
      Japanese subjects. In addition to recovery time, also pharmacokinetics and safety of Org
      25969 were to be evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 3, 2006</start_date>
  <completion_date type="Actual">December 18, 2006</completion_date>
  <primary_completion_date type="Actual">September 22, 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time from start of administration of Org 25969 / placebo to recovery of the T4/T1 ratio to 0.9</measure>
    <time_frame>After surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time from start of administration of Org 25969 / placebo to recovery of the T4/T1 ratio to 0.7 and 0.8</measure>
    <time_frame>After surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Anesthesia, General</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>rocuronium + placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rocuronium + 0.5 mg/kg Org 25969</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rocuronium + 1.0 mg/kg Org 25969</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rocuronium + 2.0 mg/kg Org 25969</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rocuronium + 4.0 mg/kg Org 25969</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>vecuronium + placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>vecuronium + 0.5 mg/kg Org 25969</description>
  </arm_group>
  <arm_group>
    <arm_group_label>8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>vecuronium + 1.0 mg/kg Org 25969</description>
  </arm_group>
  <arm_group>
    <arm_group_label>9</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>vecuronium + 2.0 mg/kg Org 25969</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>vecuronium + 4.0 mg/kg Org 25969</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sugammadex</intervention_name>
    <description>After induction of anesthesia an intubation dose of NMBA was administered IV: either 0.9 mg/kg rocuronium (arms 2-5) or 0.1 mg/kg vecuronium (arms 7-10).
Maintenance doses of 0.1-0.2 mg/kg rocuronium IV or 0.02-0.04 mg/kg vecuronium IV could be administered if necessary.
At reappearance of T2 the randomized single dose of sugammadex (0.5 to 4 mg/kg) IV was administered.</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <arm_group_label>5</arm_group_label>
    <arm_group_label>7</arm_group_label>
    <arm_group_label>8</arm_group_label>
    <arm_group_label>9</arm_group_label>
    <arm_group_label>10</arm_group_label>
    <other_name>Org 25969</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>After induction of anesthesia an intubation dose of NMBA was administered IV: either 0.9 mg/kg rocuronium (arm 1) or 0.1 mg/kg vecuronium (arm 6).
Maintenance doses of 0.1-0.2 mg/kg rocuronium IV or 0.02-0.04 mg/kg vecuronium IV could be administered if necessary.
At reappearance of T2 the randomized single dose of placebo IV was administered</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects of ASA class 1 - 3;

          -  Subjects at least 20 years but under 65 years of age;

          -  Japanese subjects;

          -  Subjects scheduled for elective surgery in supine position and under sevoflurane
             anesthesia, in need of administration of NMBAs, with an anticipated duration of about
             1.5-3 hours;

          -  Subjects who had given written informed consent.

        Exclusion Criteria:

          -  Subjects in whom a difficult intubation because of anatomical malformations was
             expected;

          -  Subjects known or suspected to have neuromuscular disorders impairing the effect of
             NMBAs and/or significant renal dysfunction (for example a creatinine level &gt; 1.6
             mg/dl) and/or severe hepatic dysfunction.

          -  Subjects known or suspected to have a (family) history of malignant hyperthermia;

          -  Subjects known or suspected to have an allergy to narcotics, muscle relaxants or other
             medication used during general anesthesia;

          -  Subjects receiving medication expected to interfere with the rocuronium or vecuronium
             given in this trial, based on the dose and time of administration;

          -  Female subjects who were pregnant;

          -  Female subjects not using birth control or using only oral contraception as birth
             control continuously;

          -  Subjects who were breast-feeding;

          -  Subjects who had already participated in CT 19.4.208A, or in another trial with Org
             25969;

          -  Subjects who had participated in another clinical trial within 6 months of entering
             into CT 19.4.208A.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Japan</country>
  </removed_countries>
  <link>
    <url>http://www.merck.com/clinical-trials/policies-perspectives.html</url>
    <description>Click here to access a synopsis of the study results.</description>
  </link>
  <reference>
    <citation>Takeda J, Iwasaki H, Yamakage M, Ozaki M, Kawamata M, Hatano Y, Yorozuya T, Miyakawa H, Kanmura Y. [Efficacy and safety of sugammadex (Org 25969) in reversing moderate neuromuscular block induced by rocuronium or vecuronium in Japanese patients]. Masui. 2014 Oct;63(10):1075-82. Japanese.</citation>
    <PMID>25693332</PMID>
  </reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 27, 2007</study_first_submitted>
  <study_first_submitted_qc>January 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2008</study_first_posted>
  <last_update_submitted>June 14, 2017</last_update_submitted>
  <last_update_submitted_qc>June 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rocuronium</mesh_term>
    <mesh_term>Vecuronium Bromide</mesh_term>
  </intervention_browse>
  <study_docs>
    <study_doc>
      <doc_type>CSR Synopsis</doc_type>
      <doc_url>http://www.merck.com/clinical-trials/policies-perspectives.html</doc_url>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

